This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Endologix's CEO Presents At Oppenheimer 22nd Annual Healthcare Conference - Event Transcript

Most recent product introduction is a new device we called AFX, it stands for anatomical fixation which is that platform sitting on the bifurcation. The features of this new device is it got a relatively low profile system, but most importantly is this new graft materially called Strata. And I will talk to you little bit about this as we go through the presentation.

We developed a new graft material for one of our other new product called Ventana. And this graft material is very, very strong and highly conformable and crates very good sealing characteristics for the device.

From the sales perspective, at the end of the third quarter we had 72 reps and clinical specialist. We plan next year to be at 66 reps and 11 clinical specialist, they are total of 77 feet on the street in the United States. As you can see over 400 years of EVAR experience, it's important to know that the reps and the clinical specialist work every case. So, we have somebody there to support the doctor for all their procedures and we just this last quarter transition to direct sales operation in Europe, previously we sold in most of Western Europe through our distribution partner and are now in the process of building our own team. We plan to finish this year with about 12 full time folks on the ground in Europe and grow that up by the end of next year to about 30, still covered in Asia and Latin America through dealers.

Read the rest of this transcript for free on

3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs